source
- Encoded Therapeutics secures $275M Series F to push Dravet gene therapy and expand manufacturingEncoded Therapeutics, a biotech focused on neuro‑genetic disorders, announced a $275 million Series F financing round. The capital was co‑led by Google Ventures and an undisclosed healthcare fund,…
- Tyra Biosciences reports phase 2 bladder cancer data, complete response rates miss analyst targets, shares slideTyra Biosciences disclosed early phase 2 results for its FGFR3‑selective inhibitor dabogratinib in patients with low‑grade, intermediate‑risk non‑muscle‑invasive bladder cancer. The trial evaluate…Fierce Biotech · 2mo agoNegative readoutNegative